EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society

Yoshito Tomimaru, Hidetoshi Eguchi, Yoshimitsu Shimomura, Tetsuhisa Kitamura, Yosuke Inoue, Yuichi Nagakawa, Akihiro Ohba, Shunsuke Onoe, Michiaki Unno, Daisuke Hashimoto, Shoji Kawakatsu, Tsuyoshi Hayashi und 7 weitere

Journal of Gastroenterology · 2023-08 · 58 (8) · 790-799

DOI: 10.1007/s00535-023-01988-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 17.06.2023. Verfasst von Yoshito Tomimaru und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka E-2, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Osaka University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Based on the Japan Adjuvant Study Group of Pancreatic Cancer-01 results, S-1 adjuvant chemotherapy has been the standard in resected pancreatic ductal adenocarcinoma (PDAC) patients in Japan and elsewhere, initiated within 10 weeks after surgery. To assess the clinical impact of this timing, we conducted a secondary analysis of a nationwide survey by the Japan Pancreas Society.

Methods

A total of 3361 patients were divided into two groups: 2681 (79.8%) initiating the therapy within 10 weeks after surgery (standard) and 680 (20.2%) after 10 weeks (delayed). We compared recurrence-free survival (RFS) and overall survival (OS) using the log-rank test and Cox proportional hazards model with conditional landmark analysis between the groups. Results were verified by adjustment with inverse-probability-of-treatment weighting (IPTW) analysis.

Results

The median timing of S-1 adjuvant chemotherapy initiation was 50 days (interquartile range: 38–66). In the standard group, 5-year RFS and OS rates were 32.3–48.7%, respectively, compared with 25.0–38.7% in the delayed group. Hazard ratios (HRs) and 95% confidence intervals were 0.84 (0.76–0.93) for RFS ( p < 0.001) and 0.77 (0.69–0.87) for OS ( p < 0.001). The IPTW analysis yielded 5-year RFS rates of 32.1% and 25.3% in the standard versus delayed group, respectively [ HR = 0.86 (0.77–0.96), p < 0.001] and 5-year OS rates of 48.3% and 39.8%, respectively [ HR = 0.81 (0.71–0.92), p < 0.001].

Conclusions

Initiation of S-1 adjuvant chemotherapy in resected PDAC patients within 10 weeks after surgery may offer survival benefit over later initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansJapanChemotherapy, AdjuvantPancreasRetrospective Studies

Stichwörter der Autor:innen

Adjuvant chemotherapyInitiationPancreatic cancerS-1Survival

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka E-2, Suita, Osaka, 565-0871, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka E-2, Suita, Osaka, 565-0871, Japan. heguchi@gesurg.med.osaka-u.ac.jp.
  • Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Osaka University, Suita, Japan.
  • Department of Hematology, Kobe City Organization Kobe Medical Center General Hospital, Kobe, Japan.
  • Division of Hepatobiliary-Pancreatic Surgery, Cancer Institute Hospital, Tokyo, Japan.
  • Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.

Förderung

  • Osaka University

Zitieren

APA

Tomimaru, Y., Eguchi, H., Shimomura, Y., Kitamura, T., Inoue, Y., Nagakawa, Y., Ohba, A., Onoe, S., Unno, M., Hashimoto, D., Kawakatsu, S., Hayashi, T., Higuchi, R., Kitagawa, H., Uemura, K., Kimura, Y., Satoi, S., Takeyama, Y., & Committee of Clinical Research, Japan Pancreas Society (2023). Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society. Journal of Gastroenterology, 58(8), 790-799. https://doi.org/10.1007/s00535-023-01988-7

Vancouver

Tomimaru Y, Eguchi H, Shimomura Y, Kitamura T, Inoue Y, Nagakawa Y, et al. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society. Journal of Gastroenterology. 2023;58(8):790-799. doi:10.1007/s00535-023-01988-7

BibTeX
@article{Tomimaru2023,
  author = {Tomimaru, Yoshito and Eguchi, Hidetoshi and Shimomura, Yoshimitsu and Kitamura, Tetsuhisa and Inoue, Yosuke and Nagakawa, Yuichi and Ohba, Akihiro and Onoe, Shunsuke and Unno, Michiaki and Hashimoto, Daisuke and Kawakatsu, Shoji and Hayashi, Tsuyoshi and Higuchi, Ryota and Kitagawa, Hirohisa and Uemura, Kenichiro and Kimura, Yasutoshi and Satoi, Sohei and Takeyama, Yoshifumi and Committee of Clinical Research, Japan Pancreas Society, Committee of Clinical Research, Japan Pancreas Society},
  title = {Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society},
  journal = {Journal of Gastroenterology},
  year = {2023},
  volume = {58},
  number = {8},
  pages = {790--799},
  doi = {10.1007/s00535-023-01988-7}
}
Kostenlos starten →